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The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a
monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies
was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. Medline
and other databases were searched. Heterogeneity was explored through I2 associated with a p-value. Of
739 identified publications, 25 were included in the meta-analysis. The global evaluation of Cochrane resul-
ted in 19 studies with a high level of bias and six with unclear risk. Due to the lack of information in primary
studies, direct meta-analyses were conducted only for amfepramone and mazindol. Compared to placebo,
amfepramone resulted in higher weight loss in the short-term (o180 days; mean difference (MD) -1.281 kg;
po0.05; I2: 0.0%; p=0.379) and long-term (X180 days; MD -6.518 kg; po0.05; I2: 0.0%; p=0.719). Only studies
with long-term follow up reported efficacy in terms of abdominal circumference and 5-10% weight reduction.
These results corroborated the finding that the efficacy of amfepramone is greater than that of placebo.
Treatment with mazindol showed greater short-term weight loss than that with placebo (MD -1.721 kg; po0.05;
I2: 0.9%; p=0.388). However, metabolic outcomes were poorly described, preventing a meta-analysis. A mixed
treatment comparison corroborated the direct meta-analysis. Considering the high level of risk of bias and the
absence of important published outcomes for anti-obesity therapy assessments, this study found that the
evaluated drugs showed poor evidence of efficacy in the treatment of overweight and obese patients. Robust
safety data were not identified to suggest changes in their regulatory status.
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’ INTRODUCTION
According to the World Health Organization, approxi-
mately 39% of adults were obese or overweight in 2014 (1).
This population is subject to associated co-morbidities, such as
diabetes mellitus type 2, hypertension, coronary heart disease
and high risk of death (1–3). Thus, how obesity and its com-
plications burden the health system is readily apparent. The
Finkelstein et al. study conducted in the United States found
that medical costs in patients with obesity in 2006 were 41.5%
higher than that for patients of normal weight. In Brazil, the
estimated annual costs for all diseases related to overweight
and obese patients are $2.1 billion; approximately 10% of these
costs can be attributed to being overweight or obese (4).
Treatment of obese and overweight patients is based
on behavioral changes, diet and exercise, with or without
pharmacotherapy or bariatric surgery, aiming to lose weight
and decrease risk factors (5). Pharmacological options are
being studied and have been available in the market since
the 1930s. Despite its long history, pharmacotherapy remains
the main tenet of scientific and political debate. There is
great concern about effectiveness and safety, as many drugs
previously available in the market were withdrawn due to
the increased incidence of psychiatric and cardiac disorders.
Moreover, the addictive effects of drugs, such as rimonabant,DOI: 10.6061/clinics/2017(05)10
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fenfluramine and sibutramine, are a major concern (6). Cur-
rently, divergences among regulatory agencies are observed.
The US Food and Drug Administration (FDA) approved the
use of amfepramone (diethypropion), benzphetamine, bupro-
pion + naltrexone, phendimetrazine, phentermine, phenter-
mine + topiramate, liraglutide, lorcaserin and orlistat. The
European Medicines Agency (EMA) only recorded bupropion
+ naltrexone, liraglutide and orlistat. In Brazil, the Agência
Nacional de Vigilância Sanitária (Anvisa) approved orlistat,
sibutramine, liraglutide and lorcaserin. Moreover, amfepra-
mone is marketed in Mexico, Chile and other countries in
Latin America, and mazindol is used in Canada, Japan and
several countries in Latin America. For many years, Brazil was
mentioned as one of the largest consumers of appetite
suppressants in the world, with evidence of irrational use of
this drug class (7–10). Therefore, the country was the site of a
debate that divided the Anvisa and medical societies over the
maintenance record of amfepramone, mazindol and fenpro-
porex. The Chamber of Deputies of Brazil is still discussing an
attempt to halt the cancellation of amfepramone, mazindol
and fenproporex use, with the justification that the population
has few therapeutic options (11). A feasible explanation lies
in the low quality of primary and secondary studies that
have already been published. Although differences between
Anvisa, FDA, EMA and others countries are likely to occur,
all organizations are strongly dependent on the quality of
randomized clinical trials (RCT) (12,13). Treatment disconti-
nuation, small sample size, low methodological quality and
high levels of heterogeneity in meta-analyses are the most
common limitations (14–16).
It is therefore important to conduct primary and secondary
studies with low risks of bias to serve as cornerstones for
political decisions regarding the appropriate regulation of
drugs and their use in clinical practice.
Therefore, our study aimed to assess the efficacy and safety
of amfepramone, fenproporex and mazindol as a monother-
apy for the treatment of obese or overweight patients using a
systematic review followed by a meta-analysis.
’ METHODS
Standard systematic review and meta-analytic methods
were used to conduct and report this analysis (17,18).
Sources of information and search
A search was conducted in Medline (via PubMed),
SCOPUS, Scielo and the Directory of Open Access Journals
until March 2016. Manual searches in the references of the
included studies were also performed. The terms used were
diethylpropion, amfepramone, diethylpropione, anfepramone, tenu-
ate, femproporex, fenproporex, perphoxene, mazindol, mazindole
and sanorex (the search strategy is available in the Supple-
mental Materials).
The assessed population comprised obese or overweight
individuals, taking into account criteria defined by clinical
studies, with or without co-morbidities, and without restric-
tions of age or gender. It excluded studies undertaken
in pregnant women; nursing mothers; or patients with
hyperthyroidism, pheochromocytoma, glaucoma, prostate
adenoma, kidney failure and liver failure. Publications
related to congress abstracts, letters, editorials, news and
studies that did not exactly report treatment were also
excluded.
Primary studies (RCT, cohort, case-control, case report)
were included in our systematic review if they assessed the
efficacy or safety of amfepramone, fenproporex or mazindol
regardless of treatment duration; controlled by placebo, diet,
physical activity or another active drug; reporting one or more
of weight change, abdominal circumference or frequency of
patients who reached 5% or 10% weight loss or metabolic bio-
markers; and withdrawal due to adverse reactions (qualitative
or quantitative).
Study selection and risk of bias in each study
Two independent reviewers (BSR and RCL) performed the
search and study selection. Data extraction was performed
by RCL and fully reviewed by BSR. Disagreements were
settled by an opinion of a third researcher (CJC). Only
studies reported in Portuguese, English and Spanish were
assessed.
The Cochrane tool was adopted to evaluate the quality of
the included studies (19).
Direct meta-analysis and network meta-analysis
Extracted data were organized and analyzed in the
Comprehensive Meta-Analysis software for direct meta-
analysis, which applied the random-effects model to predict
a high level of heterogeneity among studies. Odds ratios
(OR) were applied as effect measurements for dichotomous
outcomes, whereas mean differences (MD) were used for
continuous outcomes. The statistical method for both out-
comes was the inverse of variance. The results are presented
with 95% confidence intervals (95% CI). Following the
Cochrane recommendation, we did not assess publication
bias, as none of the meta-analyses included 10 or more
studies. Therefore, Egger regression or funnel plot statistical
tests were not developed (19). Sensitivity analysis was
performed to identify studies likely to increase heterogeneity.
Network meta-analysis using consistency or inconsistency
models were built using Addis version 1.16.6 software,
(Drugis, Groningen; The Netherlands). A potential scale
reduction factor (PSRF) of convergence assessment close to
1.00 (1oPSRFp1.05) points indicated that convergence was
matched among simulations. Bayesian random effect models
were used to assess strategies. The results were expressed by
means of credibility intervals of 95% (CrI 95%). Effect mea-
surements for continuous outcomes were MD, whereas OR
was used for dichotomous outcomes. The placebo was set as
the control.
’ RESULTS
Our systematic review identified 739 studies published in
the assessed databases. Of these, 85 were excluded after full
assessment (See Excluded studies in the Supplemental
Materials); 31 and 25 were included in our systematic review
and the quantitative analysis, respectively (Figure 1).
Study characteristics
The included studies comprised RCT (n=25) (20–44) and
case reports (n=6) (45–50). Cohort and case-control studies
that complied with our inclusion criteria were not identified.
Considering only RCTs, the studies were published from
1967 to 2014, mainly in the United States (n=9). Data from
1,965 patients were assessed (median: 50; IIQ 25-75%: 28-80),
and 19 studies took into account male and female subjects.
However, data from women were more commonly observed
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(n=965). Twenty-three studies assessed adults, 12 assessed
elderly people, 7 assessed adolescents and 2 assessed child-
ren. One study did not report age groups. Only 6 studies
reported the presence or absence of co-morbidities. Efficacy,
safety and metabolic biomarker findings were collected for
amfepramone (n=13), mazindol (n=13) and fenproporex
(n=1). The most common comparator was placebo (n=25).
There were two head-to-head studies comparing d-amphe-
tamine (n=1), mazindol (n=1), fenproporex (n=1) and sibu-
tramine (n=1).
The majority of studies had a follow up of up to 12 weeks
(84 days) (median: 84, IIQ 25-75%: 56-84). Two studies
applied the methodology of intention-to-treat for assessing
results (28,41) (see characteristics of the included studies in
our systematic review in the Supplemental Materials).
Risk of bias in RCT
Considering the Cochrane tool for risk of bias, the global
evaluation resulted in 19 studies with high risk of bias and 6
with uncertain risk.
The domains presenting more risk of bias were related to
selective reporting (n=9) and other sources of bias (n=11). In
the first case, despite no studies reporting any a priori project
protocol, most studies reported parameters and outcomes of
interest in the Methods section, regardless of the lack of
results. For the second source of bias, pharmaceutical com-
panies responsible for marketing the drug under assessment
were the funding source. Eleven studies mentioned the fund-
ing source, whereas 14 did not disclose this information in
the conflict of interest statement (see chart of risk of bias in
RCT described in the Supplemental Materials).
Synthesis of Results
Direct meta-analysis
Efficacy. Only RCTs assessing amfepramone and
mazindol compared to placebo were included in the direct
meta-analysis.
Treatment with amfepramone led to greater loss of body
weight than treatment with placebo in all studies (28,30,37,
38,41,44) regardless of daily dosage and treatment duration
(MD =-1.291 kg (95% CI: -1.548; -1.035), heterogeneity test
p=0.000; I2: 85.5%). After subgroup analysis of treatment
duration (short-term: o180 days and long-term: 4180 days)
Figure 1 - PRISMA flow chart. DOAJ: Directory open access journal.
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and sensitivity analysis (hypothetic exclusion of Ramos et al.
1964), the result increased to MD=-1.375 kg (95% CI: -1.630;
-1.121) and heterogeneity I2: 85.5% (p=0.000). Nevertheless,
homogeneity was identified among studies assessing short-
term MD=1.281 kg (95% CI: -1.538; -1.024; p=0.379; I2: 0.0%).
For studies assessing long-term results, MD=-6.518 kg
(95% CI: -8.419; -4.617; p=0.719; I2: 0.0%) (see Summary of
findings: efficacy, safety and metabolic outcomes in the
Supplemental Materials). Ramos et al. (1964) was identified
as the study responsible for a high level of heterogeneity in
global analysis. This may have been due to the dosage asses-
sed (25 mg/tid (ter in die) instead of 75 mg/qd (quaque die))
and the methodological quality (37).
The two studies assessing long-term treatment also repor-
ted efficacy according to abdominal circumference and 5%
and 10% weight reductions, confirming the efficacy of
amfepramone over placebo (see summary of findings:
efficacy, safety and metabolic outcomes in the Supple-
mental Materials).
From five studies included in the mazindol meta-
analysis, four presented body weight reductions greater
than the placebo (MD=-2.396 kg; 95% CI: -3.469; -1.323; I2:
77.6%; p=0.001) (21,29,32,33,42). In the sensitivity analysis,
the result dropped to MD=-1.721 kg after removing Heber
et al. (32) (95% CI: -2.164; -1.278; I2: 0.9%; p=0.388). Heber
et al. identified MD strongly favoring mazindol compared
to the other studies, without a reasonable explanation for
such a difference (see summary of findings: efficacy, safety and
metabolic outcomes in the Supplemental Materials).
Safety. The treatment included in the safety meta-
analysis corresponded to short-term studies only and assessed
the following outcomes: individuals presenting one or more
adverse reactions, withdrawal due to adverse reactions (see
summary of findings: efficacy, safety and metabolic outcomes
in the Supplemental Materials) and probability of specific
adverse reactions (see summary of findings: adverse reactions
in the Supplemental Materials).
Considering the six included studies in the probability of
adverse reactions meta-analysis (20,23,24,27,34,35), only one
presented results favoring the placebo (52.0% vs. 28.8%) (27),
with an OR=1.847 (95% CI: 1.057; 3.229); I2: 0.0%; p=0.619) (see
summary of findings: efficacy, safety and metabolic outcomes
in the Supplemental Materials). Studies showing greater
withdrawal due to adverse reactions in the amfepramone
group were not identified. Studies assessing amfepramone
reported nausea, dry mouth, constipation, stomach dis-
comfort, dizziness, insomnia, headache, tremor, somnolence,
tension and irritation as the most common adverse reactions.
Nevertheless, only dry mouth was associated with amfepra-
mone treatment (OR=2.430; 95% CI: 1.248; 4.729; I2: 0.0%;
p=0.651) (see summary of findings: adverse reactions in the
Supplemental Materials).
Out of five studies included in the probability of adverse
reactions meta-analysis, only one pointed to a greater risk
for such outcomes in the mazindol group (31), generating
an OR=4.086 (95% CI: 1.780; 9.376; I2: 0.0%; p=0.53) (see
summary of findings: efficacy, safety and metabolic outcomes
in the Supplemental Materials). The meta-analysis results
showed a higher risk of discontinuation in the mazindol group
(OR=2.760; 95% CI: 1.472; 5.175; I2: 0.0%; p=0.949) (see
summary of findings: efficacy, safety and metabolic outcomes
in the Supplemental Materials). The most common adverse
reactions reported were palpitations, rash, nausea, dry mouth,
constipation, bad taste sensation, vomiting, dizziness, insom-
nia, headache, tension, irritation, dysuria and chills. Only
insomnia and constipation were associated with mazindol
treatment (OR=8.083; 95% CI: 1.782; 36.674; I2: 0.0%; p=0.910)
and OR=3.906 (95% CI: 1.156; 13.197; I2: 0.0%; p=0.910),
respectively (see summary of findings: adverse reactions in the
Supplemental Materials).
Adverse reactions described in the identified case reports
for amfepramone were paranoid ideation, restlessness, apha-
sia, transient ischemic attacks due to vasospasm, schizophre-
nia, psychotic symptoms, dry mouth, constipation, dizziness
and chronic bronchitis (45–48,50), and reactions to fenpro-
porex were withdrawal syndrome, aggression, anxiety,
irritability, nightmares and insomnia, followed by severe
depression and attempted suicide (49).
Metabolic outcomes. It was only possible to carry
out meta-analyses for total cholesterol change after mazin-
dol treatment. Despite two studies identifying a decrease
in total cholesterol (p=0.000) (22,39), our meta-analysis
showed high heterogeneity (OR=-21.750 mg/ dL; 95% CI:
-39.514; -3.987; I2: 95.3%; p=0.000), not justified by dosage
difference, treatment duration, sample size or study quality
(see summary of findings: efficacy, safety and metabolic
outcomes in the Supplemental Materials).
In addition to total cholesterol, the following outcomes
were also reported: changes in fasting glucose, serum trigly-
cerides, systolic blood pressure, diastolic blood pressure and
heart rate. However, meta-analysis was prevented since
primary data were reported incorrectly or only qualitatively.
Network meta-analysis. All evaluations were split into
short-term (Table 1) and long-term treatments (Table 2).
Outcomes that presented statistical significance were change
in body weight, favoring amfepramone and mazindol
compared to placebo (Table 1), and discontinuation due to
adverse reactions, favoring placebo compared to mazindol
(Table 1). Regarding adverse reactions, somnolence and
insomnia demonstrated statistical significance. The first
favored placebo over amfepramone, and the second favored
placebo over mazindol (Table 1). All efficacy outcomes
assessing long-term treatment favored amfepramone over
placebo (Table 2). Due to a closed circuit of evidence, it was
not possible to conduct inconsistency analyses. More
information on the network meta-analysis is available in
the Supplemental Materials.
’ DISCUSSION
Relevance for decision making
Canada, USA, Japan, Brazil, Mexico, Chile and several
countries in Latin America have discussed the regulatory
status of anorectics as well as updated their regulations for
the registration and trade of these drugs. In an official report
in 2007 (51), the US FDA required the following criteria for a
drug to be registered as an anti-obesity drug: promote statis-
tically significant weight loss compared to placebo in 45%
of subjects within one year of treatment or 435% of subjects
reaching45% weight loss. The FDA also requested evidence
that new drugs are capable of improving metabolic bio-
markers, including blood pressure, lipids and glucose (51).
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Our review identified only two studies, of 6 and 12 months
of follow up, that reported the outcome of 45% weight loss
(28,41). The first identified 66.7% of patients reaching such an
outcome with amfepramone treatment compared to 25% in
the placebo group. The second aforementioned study, asses-
sing amfepramone, fenproporex, mazindol, fluoxetine and
sibutramine treatment, identified 71.4%, 69.0%, 72.4%, 34.5%
and 73.3%, respectively, of patients reaching body weight
loss of 45% compared to 34.4% in the placebo group. These
studies also reported metabolic biomarkers in a way that
prevented their use in a meta-analysis framework. Among
the identified studies assessing short-term treatment, none
reported losses of 5% or 10% weight loss, and only two repor-
ted data capable of use in meta-analysis, presenting a high
level of heterogeneity (22,39). Therefore, according to our
systematic review, amfepramone, mazindol and fenproporex
do not have enough evidence to comply with the efficacy
criteria of the FDA.
Safety parameters, especially related to major adverse
reactions, were not identified in clinical trials for the assessed
drugs, qualitatively or quantitatively (52). Contributing factors
may include the lack of separation of major and minor adverse
reactions in primary studies and the small sample size. To cor-
roborate such data, observational studies were searched, identi-
Table 1 - Network meta-analysis: short-term treatments.
Efficacy – Mean difference (CrI 95%) – Cut-off =0
Change in body weight AMFEPRAMONE - -
0.61 (-1.26, 2.27) MAZINDOL -
-1.51 (-3.16, -0.32) -2.12 (-3.28, -1.14) PLACEBO
Safety and tolerability – Odds ratio (CrI 95%) – Cut-off =1
Discontinuation due to
adverse reactions
AMFEPRAMONE 0.61 (0.12, 3.46) 1.20 (0.44, 2.89) Participants at least on
adverse reaction
0.51 (0.07, 5.52) MAZINDOL 1.97 (0.43, 7.38)
2.43 (0.36, 19.37) 4.38 (1.89, 16.38) PLACEBO
Adverse reactions – Odds ratio (CrI 95%) – Cut-off =1
Constipation AMFEPRAMONE 0.20 (0.01, 2.15) 0.93 (0.24, 2.92) Nausea
0.38 (0.02, 5.06) MAZINDOL 4.48 (0.62, 52.81)
1.58 (0.16, 13.41) 4.10 (0.81, 38.94) PLACEBO
Dizziness AMFEPRAMONE 0.00 (0.00, 0.03) 1.20 (0.21, 11.90) Insomnia
1.39 (0.23, 12.64) MAZINDOL 6.17x108 (48.29, 5.08x1019)
2.21 (0.64, 9.22) 1.56 (0.34, 6.18) PLACEBO
Headache AMFEPRAMONE 0.12 (0.00, 1.85) 0.94 (0.28, 3.45) Irritation
0.99 (0.14, 5.28) MAZINDOL 7.57 (0.73, 264.30)
0.98 (0.31, 2.29) 1.00 (0.21, 4.57) PLACEBO
Dry mouth AMFEPRAMONE 0.00 (0.00, 0.26) 0.00 (0.00, 0.28) Vomiting
0.92 (0.09, 7.69) MAZINDOL 1.63 (0.06, 77.49)
2.77 (0.89, 11.87) 3.04 (0.60, 23.89) PLACEBO
Somnolence AMFEPRAMONE 0.48 (0.04, 4.03) 1.21 (0.37, 3.22) Tension
2.09 (0.00, 1132452.48) MAZINDOL 2.40 (0.37, 21.32)
1240.03 (1.17, 5.63x107) 402.06 (0.46, 7.63x107) PLACEBO
Lower triangle, left: treatment in the column compared to treatment in the row. Upper triangle, right: treatment in the row compared to treatment in the
column. Bolded values indicate statistically significant differences.
Table 2 - Network meta-analysis: long-term treatments.
Efficacy – Mean difference (CrI 95%) – Cut-off=0
Change in body weight AMFEPRAMONE -2.09 (-9.21, 4.97) -3.30 (-9.99, 3.39) -6.51 (-11.64, -1.51) Change in waist circumference
-1.99 (-9.13, 4.99) FENPROPOREX -1.23 (-8.82, 6.46) -4.38 (-11.84, 2.63)
-2.36 (-9.05, 4.52) -0.31 (-7.66, 7.24) MAZINDOL -3.20 (-10.10, 3.49)
-6.57 (-11.83, -1.36) -4.53 (-11.72, 2.46) -4.16 (-11.06, 2.46) PLACEBO
Efficacy and safety – Odds ratio (CrI 95%) – Cut-off =1
10% weight loss AMFEPRAMONE 1.20 (0.18, 8.15) 0.99 (0.13, 7.00) 5.56 (1.30, 25.11) 5% weight loss
3.64 (0.13, 84.38) FENPROPOREX 0.84 (0.10, 6.86) 4.56 (0.66, 34.33)
3.06 (0.13, 77.72) 0.86 (0.03, 24.94) MAZINDOL 5.51 (0.79, 40.82)
33.26 (2.73, 577.98) 9.38 (0.38, 291.18) 10.97 (0.42, 324.51) PLACEBO
AMFEPRAMONE 1.64 (0.20, 19.53) 3.89 (0.31, 150.48) 1.24 (0.24, 6.39) Discontinuation due to
adverse reactions
FENPROPOREX 2.45 (0.14, 117.99) 0.78 (0.06, 6.97)
MAZINDOL 0.33 (0.01, 3.76)
PLACEBO
Lower triangle, left: treatment in the column compared to treatment in the row. Upper triangle, right: treatment in the row compared to treatment in the
column. Bolded values indicate statistically significant differences.
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fying only six case reports that included cases of addiction and
psychotic disorders. Case report studies often describe unpub-
lished or unknown outcomes of a given treatment (53).
Importance for research
The systematic review followed by meta-analysis sum-
marized several efficacy and safety results comparing wei-
ght loss promoted by pharmacotherapeutic treatment and
dieting versus weight reduction only from dieting (54). The
main limitations of this analysis reside in the short-term
monitoring of clinical trials and the lack of analysis by sub-
populations, which limit the use of the results in the clinical
population given the heterogeneity of obese and overweight
patients. To date, systematic review followed by meta-analysis
covering the three drugs evaluated here has not been performed.
The most common efficacy outcome reported in the
included studies was mean difference in weight loss between
groups. As already discussed, 5% or 10% weight loss was
rarely described in RCTs. Jensen et al. recommend an initial
target reduction of 5-10% of baseline weight within six
months of treatment (5). Metabolic biomarkers were poorly
reported, whereas for safety, the risk of withdrawal due to
adverse reactions and the description of any adverse event
experienced were the most common outcomes. The National
Obesity Observatory Standard Evaluation Framework (NOO
SEF) (55) recommends that at minimum, weight and height
measurements must be reported for the assessment of inter-
ventions at three different time points within one year of
follow up (55). Another concern is the report of different
results during treatment. In most RCTs, the results were not
divided across the follow up but instead pooled into one
single mean, counteracting NOO SEF recommendations.
The majority of our meta-analysis presented low hetero-
geneity, which can be explained by the identification bias of
heterogeneity, since our meta-analysis comprised few studies
and small populations. Hippel (2015) identified that true
heterogeneity is more likely to be seen when more studies are
included. However, there is not a consensus about the mini-
mum number of studies to carry out a meta-analysis (56,57).
Therefore, despite having a small number of meta-analyses
with heterogeneity, we cannot exclude the chance of being
unable to identify true heterogeneity.
Some RCTs have important limitations that are not sensi-
tive to the Cochrane tool, such as the lack of a thorough
description of the population under assessment. Most pri-
mary studies assessed obese or overweight adults with or
without co-morbidities, reporting pooled results. This prac-
tice leads to high heterogeneity and results that are difficult
to use in clinical practice. Such data will hardly clarify deci-
sions for decision makers and clinicians, as results such as
these are not representative of specific patient profiles (5).
The risk of bias identified through the Cochrane tool is
high, which required us to cautiously interpret the results.
According to the Cochrane tool, the most important risk of
bias lies in the conflict of interest of researchers, as pharma-
ceutical companies funded the majority of studies. An obser-
vational study of 370 RCTs revealed that funding source,
treatment effect and double-blinding are the most relevant
predictors of statistically significant results (58).
Other observed limitations were small sample size, low
number of head-to-head studies, poor description of therapy
adhesion, frequency of major adverse reactions and changes
in metabolic biomarker outcomes. Discontinuation of
treatment, small sample size, low methodological quality
and high level of heterogeneity in the meta-analyses were the
most common limitations (14–16).
The limitations of this review include the following: a) The
review of gray literature (dissertations, theses, abstracts) was
absent. Since the three evaluated drugs have over 50 years
of marketing and research, and two of them are no longer
marketed in major agencies, there was a low probability of
identifying studies of interest. Furthermore, a manual search
was performed both in the reference lists of included studies
and in official materials of companies and organizations,
which resulted in 116 identified publications. b) There was
also a language limitation; however, its effect was limited to
the exclusion of a study published in Polish. c) With respect
to inadequate reporting of dichotomous or continuous data
in the primary study, we chose to not contact the authors of
the studies to obtain raw data, considering the publication
dates extended into past decades (23 of 25 studies were
published from 1961 to 1987), and we thus had a low pro-
bability of success in contact. d) The effects of the combi-
nation of drugs with lifestyle changes, including diet and
exercise, were not considered in the analysis; although most
studies combined medications with lifestyle changes, they
did not report the proposed interventions in detail (e.g.,
calorie deficit, intensity of physical activity, duration). e) The
network meta-analysis was performed containing only pla-
cebo as the common comparator, which stems from the lack of
clinical trials with head-to-head comparisons.
More studies are needed on the safety of the evaluated
drugs, principally based in real practice, to have a stronger
basis for recommendations to regulatory bodies or health
institutions regarding the anorectic drugs evaluated. Future
RCTs should be controlled by active drugs, and the results of
these trials should be reported in terms of abdominal circum-
ference, change in body weight, the number of participants
who achieved a loss of 5-10% of body weight and any impact
on metabolic biomarkers over the course of 3, 6, 9 and
12 months. Some population subgroups have plenty of data in
the literature. Thus, they have the potential to be further
explored in future assessments as obese or overweight adults
without co-morbidities, obese adults with diabetes type II,
overweight adults with diabetes type II, obese or overweight
adults with hypertension and adolescents and children with-
out co-morbidities.
The majority of identified RCTs present a high risk of bias,
mostly related to conflict of interest and selective outcome
reporting. Regarding short-term treatment (o180 days),
amfepramone and mazindol are more effective than placebo
for losing weight. Nevertheless, short-term studies assessing
a decrease of 5-10% of body weight were not identified.
Mazindol was associated with discontinuation due to adverse
reactions. The most common adverse reactions caused by this
drug were constipation and insomnia. For amfepramone, dry
mouth and somnolence were the most common adverse
reactions. Long-term treatments (4180 days) only had results
favoring amfepramone (compared to placebo). Regarding
safety, associations with adverse reactions or discontinuation
due to adverse reactions were not identified. Therefore,
considering the high risk of bias and the lack of reporting
of important outcomes, such as metabolic biomarkers and
loss of at least 5% body weight, this study concludes that
amfepramone, mazindol and fenproporex have weak evi-
dence of their effectiveness in the treatment of overweight
and obese patients. In addition, robust safety data were not
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identified, which would allow for suggestions regarding short-
and long-term changes in their regulatory status.
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